Equities

GB Sciences Inc

GB Sciences Inc

Actions
  • Price (USD)0.008
  • Today's Change0.000 / -0.62%
  • Shares traded88.73k
  • 1 Year change-11.67%
  • Beta0.5026
Data delayed at least 15 minutes, as of Jul 05 2024 17:37 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

GB Sciences, Inc. is a biopharmaceutical research and development company. The Company develops disease-targeted formulations of cannabis and other plant-inspired therapeutic mixtures for the prescription drug market through its wholly owned subsidiary, GbS Global Biopharma, Inc. (GBSGB). The Company's primary focus is on preparing its lead program for the treatment of the motor symptoms of Parkinson's disease (PD) in a human clinical trial. Through GBSGB, the Company is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB has a portfolio of intellectual property containing both plant-inspired formulations and its artificial intelligence (AI)-enabled drug discovery platform, as well as research contracts and various supplier arrangements. GBSGBs intellectual property covers a range of over 65 medical conditions, from which five drug development programs are in the preclinical stage of drug development.

  • Revenue in USD (TTM)0.00
  • Net income in USD-4.03m
  • Incorporated2018
  • Employees3.00
  • Location
    GB Sciences Inc6450 Cameron St Ste 110ALAS VEGAS 89118-4337United StatesUSA
  • Phone+1 (888) 895-3594
  • Websitehttps://gbsciences.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Virax Biolabs Group Ltd0.00-1.71m2.88m5.00---------1.50-1.500.00-0.8568------0.00----------------0.0223-112.29-----100.00---162.50------
Alzamend Neuro Inc0.00-12.40m2.88m4.00---------1.87-1.870.00-0.5720.00----0.00-267.15---880.90-------------1,352.90---------20.35------
NovaBay Pharmaceuticals Inc14.23m-18.43m2.90m24.00------0.2037-108.80-108.9750.490.17491.412.9111.08593,041.70-108.92-61.51-185.74-83.8954.4759.99-77.22-86.470.7462--0.8629--2.243.32-2.66---15.46--
Petros Pharmaceuticals Inc4.69m-20.46m2.91m21.00--0.2918--0.619-7.37-7.371.681.550.15420.78582.15223,487.10-29.37-32.43-41.80-68.0569.9162.04-190.50-201.701.46--0.4284---2.83-16.1531.06------
Aditxt Inc506.45k-41.45m2.91m47.00--0.2448--5.75-109.80-109.800.74885.960.02840.92961.3410,775.53-231.82-192.78-658.00-321.59-27.22---8,149.75-7,208.650.0562-3.420.3915---30.90---18.11------
Portage Biotech Inc0.00-144.90m2.99m7.00--0.0933-----7.96-7.960.001.620.00----0.00-111.60-19.70-113.27-26.48------------0.0087-------520.10------
Zyversa Therapeutics Inc0.00-105.53m3.06m7.00--0.2727-----1,791.54-1,791.540.0013.440.00----0.00-142.87---164.77-------------17,576.860.00-------340.15------
Avenue Therapeutics Inc0.00-7.18m3.15m3.00--0.6961-----39.36-39.360.004.810.00----0.00-123.08-186.91-1,045.52-287.70------------0.00-------192.15------
GB Sciences Inc0.00-4.03m3.23m3.00---------0.0105-0.01050.00-0.01190.00----0.00-255.86-49.16---131.40--6.03---995.19---8.63---------2,715.25---60.82--
Neximmune Inc0.00-25.86m3.25m6.00--1.18-----24.16-24.160.002.160.00----0.00-130.41-115.07-183.16-165.07------------0.00------48.25---44.65--
Novelstem International Corp15.00k-4.22m3.37m15.00------224.72-0.09-0.090.0003-0.04780.0065--10.00---172.16---1,011.77-------26,418.53-----8.402.34--0.00---446.84------
Aridis Pharmaceuticals Inc22.36m-1.14m3.41m37.00------0.1525-0.1845-0.18450.7074-0.26482.40--58.45604,297.30-12.24-120.16---678.29-----5.11-1,559.63--------101.3729.1634.43---34.84--
Ensysce Biosciences Inc1.75m-11.55m3.49m7.00--0.8993--2.00-3.74-3.740.51090.51150.3886--9.06249,514.30-257.00-17.68-574.02-19.42-----661.34-715.78---6.250.0671---11.61--57.64------
Lipella Pharmaceuticals Inc477.45k-4.74m3.50m5.00--1.26--7.33-0.7633-0.76330.07470.36380.1232--6.2595,490.00-122.37---146.33-------993.39------0.00--144.15---77.81------
Data as of Jul 05 2024. Currency figures normalised to GB Sciences Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.